Sandbox:AyeshaFJ: Difference between revisions
Jump to navigation
Jump to search
Line 10: | Line 10: | ||
===Treatment=== | ===Treatment=== | ||
* Majority of COVID-19 patients with ARDS require mechanical ventilation for two weeks or more. The aim is to maintain oxygen saturation between 90 and 96%. The severe hypoxemia of the COVID-19 ARDS best responds when Positive end-expiratory pressure (PEEP) is high with Pplat ≤30 cm H2O. It is beneficial if the physician starts with higher than usual levels o PEEP (10 to 15 cm H2O). | |||
* | |||
=Cardiovascular Disorders and COVID-19= | =Cardiovascular Disorders and COVID-19= |
Revision as of 20:59, 23 June 2020
Acute Respiratory Distress Syndrome
Pathophysiology
- Patients infected with COVID‐19 exhibit coagulation abnormalities.[1] This procoagulant pattern can lead to acute respiratory distress syndrome.
Signs and Symptoms
Treatment
- Majority of COVID-19 patients with ARDS require mechanical ventilation for two weeks or more. The aim is to maintain oxygen saturation between 90 and 96%. The severe hypoxemia of the COVID-19 ARDS best responds when Positive end-expiratory pressure (PEEP) is high with Pplat ≤30 cm H2O. It is beneficial if the physician starts with higher than usual levels o PEEP (10 to 15 cm H2O).
Cardiovascular Disorders and COVID-19
Spontaneous coronary dissection
Pathophysiology In patients with an inflammatory overload, a localized inflammation of the coronary adventitia and periadventitial fat can occur. This could lead to the development of sudden coronary artery dissection in a susceptible patient. Signs and symptoms Treatment
Neurofibromatosis | |||||||||||||||||||||||||||||||||||
Neurofibromatosis 1 | Neurofibromatosis 2 | ||||||||||||||||||||||||||||||||||
NF1 tumor suppresor gene Mutation located on chromosome 17, encodes for neurofibromin | NF2 tumor suppresor gene Mutation located on chromosome 22, encodes for merlin | ||||||||||||||||||||||||||||||||||
clinical features: Cafe-au-lait spots, multiple neurofibromas and lisch nodules | Clinical features: bilateral acoustic neuromas | ||||||||||||||||||||||||||||||||||
Features of Wenicke-Korsakoff Syndrome | |
---|---|
Associated conditions |
|
Pathophysiology | Thiamine deficiency impairs ATP generation leading to neuronal dysfunction and death. It mostly has paraventricular lesions involving mammillary bodies and dorsomedial bodies. |
Clinical findings |
|
Treatment |
|
- Comedonal acne:Closed or open comedones on forehead, nose and chin.
- Inflammatory acne: Small, erythematous papules and pustules.
- Nodular acne: Large painful nodules; sinus tracts and scarring.
- Hyperkeratinization and obstruction of the pilosebacous follicles.
- Sebaceous gland enlargement and increased sebum production.
- Metabolism of sebaceous lipids by Cutibacterium acnes and release of inflammatory fatty acid.
- Follicular inflammation and rupture,
ii) Mechanical trauma/friction (excessive scrubbing, tight clothing)
iii) Comedogenic oil based skin and hair products.
iv) Excessive heat.
v) Obesity
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Criteria for the diagnosis of SLE | |
---|---|
Clinical features | Characteristics |
1)Malar rash | Fixed erythema, flat or raised, sparing the nasolabial folds |
2)Discoid rash | Erythematous raised patches with adherent keratotic scarring and follicular plugging. |
3)Photosensitivity | Rash due to unusual reaction to sunlight. |
4)Oral ulcer | Oral or nasopharyngeal ulcers, which may be painless. |
5)Arthritis | Non-erosive arthritis, involving >2 peripheral joints. |
6)Serositis | Pleuritis or pericarditis |
7)Renal disorder | Persistent proteinura ( >0.5g/24hrs) or cellular casts (red cell, granular or tubular). |
8)Neurological disorder | Seizure or psychosis, in the absence of provoking drugs or metabolic derangement. |
9)Hematological disorder | Haemolytic anemia or leucopenia (<4 x109) or lymphopenia (<1x109) or thrombocytopenia (<100x109) in the absence of offending drugs. |
10)Immunological | Abnormal titre of Anti-DNA antibodies or presence of Sm antigen or positive antiphospholipid antibodies. |
11)Anti-nuclear Antibody (ANA) | Abnormal ANA titre measured by immunofluorescence |
Diagnosis of SLE is made in an adult if 4 out of 11 features are present either serially or simultaneously. |
- Erythematous raised patches with adherent keratotic scarring and follicular plugging.
Congenital anomalies of the urinary system | |||||||||||||||||||||||||||||||||||
Kidneys | Renal pelvis | Ureter | |||||||||||||||||||||||||||||||||
Renal agenesis | Duplication of renal pelvis | Duplication of ureter | |||||||||||||||||||||||||||||||||
Renal ectopia | Congenital megaureter | ||||||||||||||||||||||||||||||||||
Horseshoe kidney | Post-caval ureter | ||||||||||||||||||||||||||||||||||
Unilateral fusion | Ureterocele | ||||||||||||||||||||||||||||||||||
Congenital cystic kidney | |||||||||||||||||||||||||||||||||||
Infantile polycystic kidney | |||||||||||||||||||||||||||||||||||
Unlilateral Multicystic Kidney | |||||||||||||||||||||||||||||||||||
Simple cyst of the kidney | |||||||||||||||||||||||||||||||||||
Aberrant renal vessels | |||||||||||||||||||||||||||||||||||
Mycosis fungoides | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stage IA-IIA | Stage IIA | Stage III | Stage IV | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
• Expectane policy • Topical steroides [IV-A] • nb-UVB[III,A] • PUVA [III-A] • Topical mechlorethamine [II,B] • Local RT [IV,A] | • Skin direct therapy(SDT) + local radiotherapy • ST[III+A] • (SDT+) retiods[III,B] • (SDT+) IFN a {III,B] • TSEBT [III,A] | • (SDT+) retinoides • (SDT+) IFNa • ECPI INFa +/- rtinoides • Low dose MTX • [IV-B] | • Gemcitabine • Liposomal doxorubicin • Brentuximab vedotin[II,B] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
• (SDT+) retinoides [III,B] • (SDT+) IFNa [III,B] • Retinoides +IFN a [II,B] • TSEBT [IV,A] | • Gemcitabin [IV,B] • Liposomal doxorubicin [IV,B] • Brentuximabvedotin [II,B] • Combinatio Cht [Iv,B] • AlloSCT[V,C] | TSEBT[LV,B] | • Combination Cht [IV,B] • AlloSCT [V,C] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
- ↑ Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M; et al. (2020). "The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome". J Thromb Haemost. doi:10.1111/jth.14854. PMID 32302448 PMID: 32302448 Check
|pmid=
value (help). - ↑ Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H; et al. (2020). "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study". Lancet Respir Med. 8 (5): 475–481. doi:10.1016/S2213-2600(20)30079-5. PMC 7102538 Check
|pmc=
value (help). PMID 32105632 PMID: 32105632 Check|pmid=
value (help). - ↑ Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J; et al. (2020). "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China". JAMA. doi:10.1001/jama.2020.1585. PMC 7042881 Check
|pmc=
value (help). PMID 32031570 PMID 32031570 Check|pmid=
value (help).